|
Uveomeningoencephalitic Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We identified three loci associated with VKH syndrome susceptibility (IL23R-C1orf141, rs117633859, P(combined) = 3.42 × 10(-21), odds ratio (OR) = 1.82; ADO-ZNF365-EGR2, rs442309, P(combined) = 2.97 × 10(-11), OR = 1.37; and HLA-DRB1/DQA1, rs3021304, P(combined) = 1.26 × 10(-118), OR = 2.97).
|
25108386 |
2014 |
|
Bone Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO-II) is a heritable bone disorder characterized by osteosclerosis, predominantly involving the spine (vertebral end-plate thickening, or rugger-jersey spine), the pelvis ("bone-within-bone" structures) and the skull base.
|
26056022 |
2016 |
|
Osteosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO-II) is a heritable bone disorder characterized by osteosclerosis, predominantly involving the spine (vertebral end-plate thickening, or rugger-jersey spine), the pelvis ("bone-within-bone" structures) and the skull base.
|
26056022 |
2016 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There was weaker evidence for iCHAV4, located 5' of ADO, associated only with ER-positive breast cancer (OR = 0.93 [0.90-0.96]).
|
26073781 |
2015 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients.
|
26395888 |
2016 |
|
Autosomal Recessive Osteopetrosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the chloride channel 7 gene (CLCN7) lead to chloride channel defect, which results in autosomal dominant osteopetrosis type II (ADO-II), autosomal recessive osteopetrosis (ARO), and intermediate autosomal recessive osteopetrosis (IARO).
|
26395888 |
2016 |
|
Uveomeningoencephalitic Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
In addition, we also successfully replicated the association of VKH syndrome with ADO-ZNF365-EGR2 in a Thai population.
|
26628628 |
2016 |
|
Pulmonary arterial hypertension
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report interventional re-opening of a PDA for reverse Potts shunt circulation 12 months after closure in a 3.8 year old child, suffering from right ventricular (RV) failure due to suprasystemic pulmonary artery hypertension (PAH) after ADO I implantation.
|
27516058 |
2017 |
|
Idiopathic pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report interventional re-opening of a PDA for reverse Potts shunt circulation 12 months after closure in a 3.8 year old child, suffering from right ventricular (RV) failure due to suprasystemic pulmonary artery hypertension (PAH) after ADO I implantation.
|
27516058 |
2017 |
|
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension.
|
27618447 |
2016 |
|
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci.
|
27618448 |
2016 |
|
Atrial Septal Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the 114 patients submitted to ADO II-AS implantation at our institution, 12 received this device as off-label treatment of paravalvular leak (n = 5), sinus of Valsalva fissuration (n = 2), accessory atrial septal defect (n = 2), muscular ventricular septal defect (n = 1), bleeding bronchial artery aneurysm (n = 1) and reverse shunt due to abnormal origin of left subclavian artery from pulmonary artery (n = 1).
|
27898501 |
2017 |
|
Bronchial artery aneurysm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among the 114 patients submitted to ADO II-AS implantation at our institution, 12 received this device as off-label treatment of paravalvular leak (n = 5), sinus of Valsalva fissuration (n = 2), accessory atrial septal defect (n = 2), muscular ventricular septal defect (n = 1), bleeding bronchial artery aneurysm (n = 1) and reverse shunt due to abnormal origin of left subclavian artery from pulmonary artery (n = 1).
|
27898501 |
2017 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Emerging evidence suggests that the adenosine (Ado) receptors may play crucial roles in tumor progression.
|
27911956 |
2016 |
|
Fenestration (morphologic abnormality)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients in whom fenestration closure was performed with an ADO II and who had at least 6 months of follow-up were included in this study.
|
28261286 |
2017 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Dyspnea
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Five clusters were identified based on three PCA components, which accounted for 60% of variance of the data.Importantly, couch potatoes (i.e. the most inactive cluster) were characterised by higher BMI, lower FEV<sub>1</sub>, worse dyspnoea and higher ADO index compared to other clusters ( p < 0.05 for all).
|
28774199 |
2017 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical Significance of DXA and HR-pQCT in Autosomal Dominant Osteopetrosis (ADO II).
|
29018903 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our analyses showed best discriminatory performance for the ADO and updated BODE scores in patients with COPD.
|
29495970 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
In primary care, ADO appears superior at predicting death in COPD.
|
29724388 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our screens also identified that the metabolic protein 2-aminoethanethiol dioxygenase (Ado) modulates sensitivity to TNF-mediated killing by cytotoxic lymphocytes and is required for optimal control of tumors in vivo.
|
29776993 |
2018 |
|
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings confirmed the association of four loci (<i>LACC1</i>, <i>CEBPB-PTPN1</i>, <i>ADO-EGR2</i> and <i>RIPK2</i>) in Chinese Han patients with BD.
|
29907633 |
2018 |
|
Immunosuppression
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, the expression of the enzyme responsible for the degradation of ADO, adenosine deaminase, was higher in tolerant patients with respect to the nontolerant group along the immunosuppression withdrawal.
|
30019408 |
2019 |